The emerging role of metabolomics in the development of biomarkers for pulmonary hypertension and other cardiovascular diseases (2013 Grover Conference series)
MetadataShow full item record
CitationLewis, Gregory D. 2014. “The emerging role of metabolomics in the development of biomarkers for pulmonary hypertension and other cardiovascular diseases (2013 Grover Conference series).” Pulmonary Circulation 4 (3): 417-423. doi:10.1086/677369. http://dx.doi.org/10.1086/677369.
AbstractAbstract The functional and prognostic significance of pulmonary hypertension (PH) is well established, yet our understanding of circulating peptides and metabolites that might mark or contribute to various forms of PH remains limited. Metabolites are the end result of all the regulatory complexity present in a cell, tissue, or organism and therefore serve as the most proximal reporters of the body’s response to a disease process or drug therapy. This review presents the rationale, methodology, and preliminary findings from studies that apply comprehensive metabolite profiling to gain knowledge of new circulating markers of PH.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:13890784
- HMS Scholarly Articles